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Abstract. The unclear role of cytokeratin (CK) in the
progression and diagnostics of malignant melanomas stimulated
us to compare the reactivity of three antibodies directed to CK in
109 paraffin-embedded melanomas. By far the majority of
melanomas did not express cytokeratin even at the<1% level,
only vimentin. In about 6% of melanomas it was possible to
find CK expression ranging between 3 and 40% of melanoma
cells. There was a correlation between CK expression and pT-
stage. Cytokeratin-expressing tumours were found in the more
advanced pT-stages. The independent prognostic values of none
of the three CK antibodies investigated could be shown.
Specific antibodies against different intermediate filaments
have been applied to establish the definitive histopathological
diagnosis of tumours and to explain their origin in
diagnostically difficult cases. 
Cytokeratins (CK) are characterized as a family of water-
soluble proteins with pH=5-8 and a molecular weight
between 40 and 68 kDa. With the help of two-dimensional
gel-electrophoresis, more than 20 cytokeratin subtypes were
identified (1-3). 
The cytokeratin pattern of different tumour types, other
than melanomas, is constant and assists in tumour
progression from the very early stage up to late metastasis. 
All melanomas are vimentin-positive in all cells. Some
melanomas are also reported to express cytokeratin. Gatter
et al., Achilles and Schröder, and Ben-Izhak were able to
demonstrate CK expression, not only in primary melanomas
but also in their metastases (4-6). The studies of Zarbo et
al. and Hendrix et al. postulated the direct connection
between CK expression and melanoma grade of malignancy,
as well as increased migration and invasivenes of melanoma
cell lines in vitro (7,8). 
The diagnostic application of CK in melanoma is mostly
connected with single CK subtypes, as for example CK18 in
uveal melanomas (9). The independent prognostic role of
CK in melanomas has not yet been demonstrated (9). 
The main objective of this study was to check the
cytokeratin reactivity in primary melanomas measured with
three different antibodies (KL1, Lu5 and A4). An additional
aim was to check whether CK expression in a minority of
melanoma cells could be used as a staging and prognostic
marker for this tumour type.
Materials and Methods
The material investigated comprised 109 primary melanomas (years
1976-1999) of different pT-stages and locations. The patient group
comprised 51 females and 58 males. The age of them ranged between
26 and 83 years, with average 57.4 years. Forty primary melanomas
were located on the trunk, 30 in the head and neck area, 25 on the
upper extremities and 14 on the lower extremities. Altogether 5 pTis,
13 pT1, 3 pT2, 40 pT3 and 20 pT4 melanomas were investigated. 
Immunohistochemistry. The tumour tissue from the Archives of the
Pathological Institute, University of Göttingen, Germany and from
the Pathological Institute of the University of Krakow, Poland was
routinely fixed in 3.6% formaldehyde and embedded in paraplast.
Three-Ìm-thick serial sections were prepared from all of the
investigated tumours. The histological microtome sections were
prepared by the same technician to ensure that the quality of the
sections stayed consistent. Disposable blades were used to achieve
the highest quality. 
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The following primary antibodies were applied for
immnunohistochemical detection of cytokeratin expession: 
- monoclonal IgG1 mouse antibody against the human cytokeratin
subtypes 1, 2, 5, 6, 7, 8, 10, 11, 14, 16, 17, 18, 19, clone KL1,
(Immunotech, Hamburg, Germany).
- mouse monoclonal Lu5 antibody directed against CK1, 5, 6, 8, 14,
18, 19, (kind support of Prof. Dr. M.Osborn, Max-Planck Institute
for Biophysical Chemistry)
- mouse monoclonal A4 antibody directed against CK8 (kind
support of Prof. Dr. M.Osborn, Max-Planck Institute for
Biophysical Chemistry, Göttingen, Germany)
- monoclonal antibody against individual cytokeratin subtypes
(Boehringer, Mannheim, Germany) each with respective
specificity for cytokeratins 4, 5/6, 7, 8, 13, 18 and 19.
The histological sections were deparaffinated by xylol and then
transferred to a descending alcohol series and rinsed with distilled
water. For immunodetection of CK expression with KL1, Lu5, A4
and with antibodies against CK subtype 5/6, 7, 8, 13 and 19,
histological sections were first transferred to distilled water and then
digested with trypsin at 37ÆC (10 minutes for KL1, Lu5 and A4, 30
minutes for the above-mentioned CK subtypes). After trypsinization,
the histological specimens were rinsed in Tris buffer. Thereafter,
incubation with the primary antibody was carried out for 2 hours at
an antibody concentration 1:2 for KL1 and CK18, 1:5 for CK 13 and
CK19, 1:10 for CK8, A4 and Lu5, 1:50 for CK4, 5/6 and CK7. Then,
the histological specimens were rinsed with Tris buffer solution and
incubated at room temperature with rabbit anti-mouse antibody
(Dako) 1:50 for 30 minutes. After the detection reaction had been
carried out using the APAAP method in combination with the
chromogen astra new fuchsin, the nuclei were counterstained with
hematoxylin. The percentage of immunolabelled tumour cells
(index) was determined in 10 high-power fields (areas measured at x
400 magnification) per histological specimen. 
Statistics. Index values were correlated with each other according
to the formula of Spearmann. The pT-stadia were compared
applying the U-Mann-Whitney tests. Five-year survival rates were
calculated according to the method of Kaplan and Meier (10). 
Results
CK expression in all melanomas investigated. Six % of all
melanomas investigated were positive in reaction with Lu5
and A4 antibodies. Three % of tumours showed positive
signals in reaction with KL1 antibody. The cytokeratin
expression measured with the Lu5 antibody oscillated between
0 and 40% of cells with a median 0%. The A4 reactivity
oscillated between 0 and 30%, with a median 0%. The KL1
index in primary melanomas reached values between 0 and
25% with a median 0% (Table I-III) (Figure 1A-D).
pTis melanomas. All the pTis melanomas did not show any
cytokeratin expression measured with the three different
antibodies (Tables I-III).
pT1 melanomas. In pT1 melanomas, KL1 and Lu5 reactivity
was not found. A4 was positive in 16% of cases, while the
percentage of positive cells ranged between 0 and 1%
(Tables I-III).
pT2 melanomas. In pT2 melanomas, 3% of cases
demonstrated Lu5 and A4 reactivity. CK-positive cells stained
with KL1 antibody in pT2 tumours were not found. The Lu5
index ranged between 0 and 5%, while the A4 index did not
exceed 1% (Table I-III).
pT3 melanomas. Nine % of the pT3 melanomas showed
both Lu5 and A4 reactivity. KL1 reactivity was found only
in 6% of pT3 tumours. The highest maximum was found for
Lu5 index (40%), middle one for A4 (30%) and the lowest
one for KL1 (25%) (Table I-III). 
pT4 melanomas. Eighteen % of pT4 melanomas were
positive in reaction with Lu5 antibody. The A4 antibody
reacted with 12% of pT4 tumours and KL1 with 6%. The
percentage of CK-positive cells did not exceed 10% in
reactions with Lu5 and A4 antibodies and 5% in reaction
with KL1 antibody (Tables I-III).
Relationship between pT-stage and cytokeratin expression.
Comparison of the cytokeratin expression in pT-stages of
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Table I. Cytokeratin expression measured with KL1 antibody.
Stage % of positive % of positive cells 
cases median minimum maximum
All melanomas 3.00 0.00 0.00 25.00
pTis 0.00 0.00 0.00 0.00
pT1 0.00 0.00 0.00 0.00
pT2 0.00 0.00 0.00 0.00
pT3 6.00 0.00 0.00 25.00
pT4 6.00 0.00 0.00 5.00
Table II. Cytokeratin expression measured with Lu5 antibody.
Stage % of positive % of positive cells 
cases median minimum maximum
All melanomas 6.00 0.00 0.00 40.00
pTis 0.00 0.00 0.00 0.00
pT1 0.00 0.00 0.00 0.00
pT2 3.00 0.00 0.00 5.00
pT3 9.00 0.00 0.00 40.00
pT4 18.00 0.00 0.00 10.00
malignant melanomas demonstrated only one significant
difference between pT2 and pT4 melanomas for Lu5
reactivity (p=0.0438).
Relationship between CK expression detected with three
different antibodies in primary melanomas. The correlation
between the results of the three immunohistochemical
reactions (KL1, Lu5, A4) demonstrating CK expression in
primary melanomas was highly significant (p<0.01).
Defining of CK pattern. Ten cases were additionally stained with
antibodies against single CK subtypes. CK18 was found in all
tumours investigated. Four out of 10 melanomas were CK13-
positive, while 2/10 demonstrated the expression of CK4 and
CK8. CK19 was positive only in 1/10 tumours (Table IV). 
Prognostic significance. Fifty-eight % of Lu5-positive and 44%
of Lu5-negative patients survived 5 years. Sixty-six % of KL1-
positive and 45% of KL1-negative melanomas showed follow-
up longer than 60 months. Forty-two % A4-positive and 43%
of A4-negative patients survived longer than 5 years. The
differences in survival between cytokeratin-positive and -
negative cases (with all three antibodies) did not reach the
level of significance (Figure 2A-C).
Discussion
Differentiation between amelanocytic melanomas and
carcinomas is often not possible by morphology alone.
Therefore, different immunohistochemical markers were
applied for this purpose. HMB 45, for example, was
demonstrated to be highly specific for pigmented
melanocytic lesions (11). 
The well known expression of cytokeratins, not only in
tumours with epithelial origin but also in primary melanomas,
makes the diagnostic role of cytokeratins doubtful. The ratio
of positive melanomas in the whole tumour collective did not
exceed 6%, which is notably less than reported by Bar and
Schlote, who found CK expression in 33% of melanomas
investigated (12). Miettinen and Fransilla demonstrated CK
in 11% of melanomas (13). These differences in cytokeratin
expression can be explained by various tumour collectives and
conditions of fixation. Paraffin embeddding and formalin
fixation irreversibly and selectively destroy the alfa-helical
conformation of the protein. However, one should not forget
that almost all histopathological diagnoses are made on
paraffin-embedded tissue and only antibodies reacting on this
type of tissue can find practical application in tumour
pathology. This study demonstrates that, besides the already
known KL1 antibody,  Lu5 and A4 can also be successfully
applied in paraffin-embedded tissue. This fact has, to our
knowledge, not yet been demonstrated.
In this study there was a tendency for the percentage of CK-
positive cases to increase parallel with the pT-stage of the
tumour. In pT4 melanomas, 18% of tumours showed reactivity
with Lu5 antibody and the percentage of CK-positive cases for
other cytokeratin antibodies (KL1, A4) was respectively lower,
but higher than in pT2 and pT3 melanomas. In contrast, all
pTis melanomas were negative. This fact demonstrates that the
expresion of cytokeratins is associated with more aggressive
and less differentiated tumours. Previous studies on melanoma
cell lines have demonstrated a positive relationship between
cytokeratin expression and the formation of adhesive sites for
melanoma cells to the intracellular matrix, as well as between
cytokeratin presence and motility and invasivenes of tumour
cells (14). These findings in cultivated melanoma cells can be
used as an attractive model for the functional relationship
between cytokeratin expression and tumour progression in
malignant melanomas.
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Table III. Cytokeratin expression measured with A4 antibody.
Stage % of positive % of positive cells 
cases median minimum maximum
All melanomas 6.00 0.00 0.00 30.00
pTis 0.00 0.00 0.00 0.00
pT1 16.00 0.00 0.00 1.00
pT2 3.00 0.00 0.00 1.00
pT3 9.00 0.00 0.00 30.00
pT4 12.00 0.00 0.00 10.00
Table IV. Analysis of cytokeratin subtypes in 10 selected melanomas.
No Stage % of positive cells for CK
4 5/6 7 8 13 18 19
1 pT1 0 0 0 0 10 90 0
2 pT2 0 0 0 0 30 85 0
3 pT2 0 0 0 0 0 90 0
4 pT3 0 0 0 12 25 80 10
5 pT3 12 0 0 0 15 40 0
6 pT3 0 0 0 0 0 50 0
7 pT3 1 0 0 0 0 90 0
8 pT3 0 0 0 0 0 90 0
9 pT4 0 0 0 0 0 85 0
10 pT4 0 0 0 5 0 70 0
The next question we tried to answer in this study was
the prognostic significance of the used markers. The study
was performed on a relatively large number of cases with
known follow-up. The application of antibodies working on
paraffin-embedded tissue allowed us to investigate cases
with almost 20 years of observation time. No significant
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Figure 1. A. Positive control in reaction with Lu5 antibody, sweat glands. B. Reactivity of Lu5 antibody in normal epidermis. C. CK-positive cells in pT4
melanoma stained in reaction with A4 antibody. D. CK-positive cells in pT4 melanoma stained with Lu5 antibody.
differences between the Kaplan-Meier curves of CK-
positive and -negative cases for the three antibodies
applied were found. This result is in agreement with the
studies of Ben-Izhak and Fuchs, who also did not find any
prognostic significance of CK expression in malignant
melanomas (6,9). 
The indices of CK measured with three different
antibodies correlated highly significant with each other.
This finding confirms the high specificity of all three
cytokeratin antibodies. The fact that a positive Lu5 index
was found in more cases and was higher than the KL1
and A4 indices demonstrates a higher sensitivity of the
Lu5 antibody in comparison to KL1 and A4, and suggests
its practical application in paraffin-embedded melanoma
specimens.
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Figure 2. A-C Kaplan-Meier survival curves for CK-positive and -negative
melanomas stained with 3 different antibodies (Lu5, A4, KL1).
